用补充抑制剂伊普塔科潘治疗自身免疫血清性贫血:一个病例报告
Xiaoqing Li1, Minran Zhou1, Sai Ma1
1Department of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Frontiers in medicine
|March 21, 2025
概括
本案例研究详细介绍了一名患有严重热抗体自身免疫溶血性贫血症 (wAIHA) 的老年男性. 用伊普塔科潘和葡萄糖皮质激素治疗迅速解决了他的血液溶解危机,并稳定了血红蛋白水平.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
背景情况:
- 自身免疫血液溶解性贫血 (AIHA) 涉及到攻击红细胞的自身抗体.
- 热型抗体类型AIHA (wAIHA) 具有在体温下有效的自身抗体的特征.
研究的目的:
- 在老年男性中呈现急性严重WAIHA病例.
- 描述患者的表现,诊断结果和治疗反应.
主要方法:
- 临床病例的介绍.
- 实验室检测结果的审查,包括血红蛋白,胆红素,LDH和直接/间接抗球蛋白测试.
- 治疗干预措施的描述:甲基普雷迪尼索隆,免疫球蛋白,伊普塔科潘和高剂量的葡萄糖皮质激素.
主要成果:
- 患者出现严重的贫血 (HGB 31 g/L),黄,以及升高的 bilirubin 和 LDH.
- 开始用甲基prednisolone和免疫球蛋白治疗后,出现了血液溶解危机.
- 随后用伊普塔科潘和高剂量的葡萄皮质激素治疗导致症状快速改善,并且在没有输血的情况下稳定血红蛋白水平.
结论:
- 伊普塔科潘与高剂量葡萄糖皮质类药物结合使用,有效地管理了waIHA的严重溶血危机.
- 这一案例突出了耐火性或严重的WAIHA的成功治疗方法.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.7K
09:57Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
11.9K
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
123
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
123
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
106
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
106
